

miRNAs (miR-146a and/or miR-142-3p) was a novel strategy for the treatment of endotoxin-induced adverse effects and mortality. Regarding drug-induced liver injury, halothane-induced,  $\alpha$ -naphthylisothiocyanate-induced, and diclofenac-induced liver injuries in mice are mediated by ILs (110–112); thus, involvement of these miRNAs could be of interest.

Cytokines decrease CYP-associated drug metabolism during inflammation and infection (113), which influences susceptibility to various drugs and toxic chemicals. IL-6 decreases both the rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4, whereas the transcriptional activities of PXR and CAR are unaffected by IL-6 (114). The generation of reactive metabolites of drugs and chemicals that are catalyzed by P450s is suggested to be a major factor in initiating drug-induced liver injury. Subsequently, the exacerbation of drug-induced liver injury is affected by increased IL expression. With respect to cytokines and drug-induced liver injury, IL-4 mediates dicloxacillin- and flutamide-induced liver injury in mice (115, 116). Th17 cell differentiation is affected by IL-6 and STAT3. IL-4, IL-5, and STAT6 are essential factors for the differentiation of Th2 cells from naive T cells. Accordingly, immune- and inflammation-mediated drug-induced liver injury might be regulated by miRNAs. We hope that the currently unreported mechanism of idiosyncratic drug-induced liver injury, in which immune- and inflammation-mediated factors are essential, will be clarified by progress in miRNA research as well as by studies of metabolic activation reactions that are catalyzed by P450s.

## miRNA-RELATED PHARMACOGENOMICS

The majority of pharmacogenomics research has focused on the role of single-nucleotide polymorphisms (SNPs). Recent large-scale studies have identified 15 million SNPs in the human genome, many of which affect gene function in promoters or in *cis*- or *trans*-regulatory elements by modifying sequences of proteins (117). Therefore, SNPs may affect activities of various enzymes and are associated with differences in drug response as well as the adverse effects of drugs and toxic chemicals. SNPs in primary miRNAs (pri-miRNAs), precursor miRNAs (pre-miRNAs), or mature miRNAs could modify various biological processes by influencing the processing or target selection of miRNAs (118, 119). SNPs in pri-miRNA or pre-miRNA are relatively rare. Only approximately 10% of human pre-miRNAs have documented SNPs, and less than 1% of miRNAs have SNPs in the functional seed sequence region (120). Although SNPs in the seed sequence region of miRNAs may be rare, these SNPs may influence the expression of hundreds of genes and related pathways. An interesting study regarding the association between SNPs in the miRNA sequence and clinical drug therapy was published by Boni et al. (121). A SNP (rs7372209) in the pri-miR-26a gene and a SNP (rs1834306) in the pri-miR-100 gene were significantly associated with the tumor response or time to progression in 61 patients with metastatic colorectal cancer who were treated with 5-fluorouracil and CPT-11 (121). This study is the first to suggest a relationship between the clinical outcome of drug therapy and SNPs in both pri-miRNAs and pre-miRNAs.

The frequency of SNPs in the MRE is low, but MRE-site polymorphisms, which affect the expression levels of relevant genes, may have a relatively higher frequency. Thus, early studies concerning miRNA in pharmacogenomics investigated SNPs in MREs on mRNAs. Many MRE-site polymorphisms are thought to be associated with phenotypes of various types of diseases because a gain of function or loss of function results in changes in the expression of target mRNAs (122). Many correlation analyses between SNPs in MREs and diseases *in vitro* or *in silico* were conducted, but only a little functional evidence has been confirmed (122). Human dihydrofolate reductase (DHFR) (123) and sulfotransferase isoform 1A1 (SULT1A1) (124) have been associated with miRNA-related polymorphisms that affect the drug response, adverse reactions, and toxicological outcomes (see below).

---

SNP:  
single-nucleotide  
polymorphism

pri-miRNA: primary  
miRNA

pre-miRNA:  
precursor miRNA

---

Approximately 20,000 MRE-site polymorphisms in miRNAs were systematically searched using Patrocles (<http://www.patrocles.org/Patrocles.htm>) and PolymiRTS (<http://compbio.uthsc.edu/miRSNP/>), databases that allow in silico predictions. However, these predictions should be carefully validated by functional studies. Recent genome-wide association studies (GWAS) performed a genome-wide scan of human variation within validated and predicted miRNA binding target sites. The genetic variants at putative miRNA binding sites are possibly functional and may contribute to phenotypic variation in drug/chemical responses and adverse reactions. From computational analyses using human whole-genome and SNP databases, 87 SNPs were identified in miRNA seed sequences, which may represent functional variants of identified GWAS SNPs (125). Furthermore, miRNAs encoding these 39 seed-site polymorphisms have been reported to be coexpressed with their predicted mRNA targets; however, functional analyses are required.

A report concerning a MRE-site polymorphism in relation to drug-metabolizing enzymes and adverse reactions has demonstrated that a C829T SNP, which occurs naturally at the MRE of miR-24 in the 3' UTR of human DHFR, causes DHFR overexpression and consequent methotrexate resistance (126). Compared with wild-type cells, cells with the mutant 3' UTR showed a twofold longer half-life of the DHFR mRNA, showed higher DHFR mRNA and DHFR protein expression levels, and were fourfold more resistant to methotrexate. In a case-control study of childhood leukemia patients, the allelic frequency of C-to-T SNPs is 14.2% in the Japanese population (123).

SULT1A1 is one of the essential enzymes in the activation or detoxification of endo- and xenobiotics as well as of dietary and environmental procarcinogens/promutagens. SULT1A1 activity showed large interindividual variability (9), which may be caused by genetic polymorphism, although the latter would not fully account for such a variation. A SNP in the 3' UTR (972C>T [rs1042157]) is significantly decreased with the SULT1A1 mRNA level ( $p = 0.029$ ) and with enzymatic activity ( $p = 0.012$ ) (124), demonstrating that miR-631 directly regulates SULT1A1 expression of the 3' UTR (SNP of 972C>T) in an allele-specific manner. This finding provides new information for risk assessment studies of heterocyclic amines such as *N*-hydroxyarylamines, *N*-hydroxy-heterocyclic amines, and aryldihydroxamic acids.

UGT2 families are important enzymes that are involved in the metabolism of multiple endobiotics and xenobiotics. Sun et al. (128) identified a SNP, c.1761T>C (rs3100), in 3' UTR of the UGT2B15 isoform; this SNP affects the expression of the UGT2B15 mRNA in HepG2, MCF-7, and Caco-2 cell lines. The location of the SNP may create or diminish an unknown miRNA binding site. Another SNP, C3435T, in exon 26 of the MDR1 gene, caused no amino acid change and was associated with the significantly lower duodenal expression of MDR1 and thereby the increased plasma concentrations of digoxin after oral administration (129). Because the full miRNA profile is unlikely to be known, an unknown miRNA binding site may be created or diminished by the SNP. Further experimental evidence is required.

In the near future, drug responses or susceptibility to xenobiotic toxicity will be predicted by large-scale GWAS and follow-up functional experiments. Data indicating which miRNAs are relevant in various phenotypic outcomes will be gathered. This new class of miRNA-related polymorphisms may contribute to the interindividual variability in adverse drug responses and toxicant-induced adverse events.

## CIRCULATING miRNA IN BODY FLUIDS AS POTENTIAL TOXICOLOGICAL BIOMARKERS

The presence of stable circulating miRNAs in serum and their potential as cancer markers was first reported by Lawrie et al. (130), and, subsequently, circulating miRNAs have been extensively

studied mainly for the diagnosis and prognosis of cancer diseases, especially at an early stage (131). However, these early studies have been limited by their lack of constant standards in quantification and by inconsistencies in methodologies. The first study of a plasma miRNA profile in liver injury was conducted by Wang et al. (132). The authors reported that acetaminophen increased the levels of miR-122 and miR-192 in mouse plasma in a dose-dependent and exposure-duration-dependent manner that paralleled that of alanine aminotransferase (ALT) and caused histopathological changes in the liver. Subsequently, increased plasma concentrations of miR-122, miR-133a, and miR-124 were reported to correspond to injuries in liver, muscle, and brain tissues, respectively, as each of these is the abundant and specific miRNA in each organ (133). The miR-122 plasma concentration increased more quickly and dramatically than did the aminotransferase activities in the blood samples of liver-injured mice, reflecting the extent of hepatocellular injury (134). This change was more specific for viral-, alcohol-, and chemical-induced liver injury than for other organ damage and was a more stable and reliable biomarker (134). The plasma miRNA profiles in the rat liver injury model could be useful in identifying specific and sensitive biomarkers for differentiating pathogenesis of acute and chronic liver injury, as well as hepatocellular injury, cholestasis, steatosis, steatohepatitis, and fibrosis (135).

These lines of data suggest that plasma miRNAs may be superior noninvasive human biomarkers in distinguishing the different types of liver injury compared with conventional biomarkers, such as ALT and alkaline phosphatase (ALP), although detailed evaluations remain to be performed. Plasma miRNAs might be used to determine the types of liver injury in order to decide on the appropriate therapy, or they might be used to clinically evaluate the progress of liver function recovery following liver injury. Urinary miRNA profiles could diagnose liver injury induced by hepatotoxicants (acetaminophen or carbon tetrachloride) in rats (136). Discerning miRNA-related associations with disease development (137) and conducting comparative miRNA expression profile studies across models will be important for a comprehensive understanding of the physiological implications of miRNA changes. Moreover, can circulating miRNAs affect other signaling pathways? Nevertheless, circulating miRNAs in biological fluids have great potential in toxicological studies, e.g., as a novel, informative, and noninvasive method for extrapolating animal toxicity data to humans.

## CONCLUSIONS

The importance of understanding the critical role of miRNAs, their involvement with drug-metabolizing enzymes and nuclear receptors, and implications for toxicological studies is recognized. Increasing interest in miRNA research creates new areas in toxicology: the effects of physiological conditions such as alcohol, diet, smoking, stress, supplements, hormones, medication, or diseases on miRNA expression; the effects of inter- and intraindividual differences in miRNA expression on drug response or susceptibility to xenobiotic toxicants; the effects of miRNA and/or target mRNA genetic polymorphisms on drug response, pharmacokinetics, and pharmacodynamics; and the identification of new noninvasive biomarkers to extrapolate animal-derived toxicology data to humans. miRNAs will contribute to the comprehensive understanding of drug- or chemical-induced toxicity, which will facilitate drug development and clinical pharmacotherapy.

## DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

## ACKNOWLEDGMENTS

This work was partially supported by a Health and Labor Science Research Grant (H23-BIO-G001) from the Ministry of Health, Labor and Welfare of Japan.

## LITERATURE CITED

1. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. 2003. New microRNAs from mouse and human. *RNA* 9:175–79
2. Hinske LC, Galante PA, Kuo WP, Ohno-Machado L. 2010. A potential role for intragenic miRNAs on their hosts' interactome. *BMC Genomics* 11:533
3. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 19:92–105
4. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. *Dev. Cell* 11:441–50
5. Krol J, Loedige I, Filipowicz W. 2010. The widespread regulation of microRNA biogenesis, function and decay. *Nat. Rev. Genet.* 11:597–610
6. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. *Annu. Rev. Biochem.* 79:351–79
7. Chekulaeva M, Filipowicz W. 2009. Mechanism of miRNA-mediated post-transcriptional regulation in animal cells. *Curr. Opin. Cell Biol.* 21:452–60
8. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.* 34:D140–44
9. Jones AL, Roberts R, Coughtrie MW. 1993. The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. *Biochem. J.* 296:287–90
10. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. *Cell* 115:787–98
11. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, et al. 2005. Combinatorial microRNA target predictions. *Nat. Genet.* 37:495–500
12. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. *Nature* 455:64–71
13. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 433:769–73
14. Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. *Nature* 460:479–86
15. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, et al. 1994. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. *J. Biol. Chem.* 269:13092–99
16. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, et al. 1996. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. *Cancer Res.* 56:2979–84
17. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 1996. 17 $\beta$ -Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. *Proc. Natl. Acad. Sci. USA* 93:9776–81
18. Henderson IC, Canellos GP. 1980. Cancer of the breast: the past decade. *N. Engl. J. Med.* 302:17–30
19. Han X, Liehr JG. 1994. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. *Carcinogenesis* 15:997–1000
20. Newbold RR, Liehr JG. 2000. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. *Cancer Res.* 60:235–37
21. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI. 1999. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. *Cancer Lett.* 139:199–205
22. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, et al. 1997. Tumor-specific expression of cytochrome P450 CYP1B1. *Cancer Res.* 57:3026–31
23. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. 2006. MicroRNA regulates the expression of human cytochrome P450 1B1. *Cancer Res.* 66:9090–98

24. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. 2004. Human *CYP1B1* is regulated by estradiol via estrogen receptor. *Cancer Res.* 64:3119–25
25. Lu Y, Cederbaum AI. 2008. CYP2E1 and oxidative liver injury by alcohol. *Free Radic. Biol. Med.* 44:723–38
26. Bolt HM, Roos PH, Thier R. 2003. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. *Int. Arch. Occup. Environ. Health* 76:174–85
27. Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, et al. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. *Pharmacogenet. Genomics* 17:731–42
28. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J. Pharmacol. Exp. Ther.* 270:414–23
29. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. 2010. Human CYP2E1 is regulated by miR-378. *Biochem. Pharmacol.* 79:1045–52
30. Lee DY, Deng Z, Wang CH, Yang BB. 2007. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fc-1 expression. *Proc. Natl. Acad. Sci. USA* 104:20350–55
31. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. 2006. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. *PLoS ONE* 1:e116
32. Kimura S, Kozak CA, Gonzalez FJ. 1989. Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene. *Biochemistry* 28:3798–803
33. Jalas JR, Hecht SS, Murphy SE. 2005. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. *Chem. Res. Toxicol.* 18:95–110
34. Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P. 2008. Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Carcinogenesis* 29:2394–99
35. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. 2007. *microRNA-34b* and *microRNA-34c* are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. *Cancer Res.* 67:8433–38
36. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. 2007. A microRNA component of the p53 tumour suppressor network. *Nature* 447:1130–34
37. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. *Clin. Pharmacokinet.* 32:210–58
38. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR. 1990. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B<sub>1</sub> metabolism in human liver. *Proc. Natl. Acad. Sci. USA* 87:8306–10
39. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ, Guengerich FP. 1989. Role of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. *Cancer Res.* 49:6304–12
40. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, et al. 2002. Co-regulation of *CYP3A4* and *CYP3A5* and contribution to hepatic and intestinal midazolam metabolism. *Mol. Pharmacol.* 62:162–72
41. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, et al. 2003. Genotype-phenotype associations for common *CYP3A4* and *CYP3A5* variants in the basal and induced metabolism of midazolam in European- and African-American men and women. *Pharmacogenetics* 13:596–606
42. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. 2005. Phenotype-genotype variability in the human *CYP3A* locus as assessed by the probe drug quinine and analyses of variant *CYP3A4* alleles. *Biochem. Biophys. Res. Commun.* 338:299–305
43. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, et al. 2002. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. *Pharmacogenetics* 12:121–32

44. Martínez-Jiménez CP, Jover R, Donato MT, Castell JV, Gómez-Lechón MJ. 2007. Transcriptional regulation and expression of CYP3A4 in hepatocytes. *Curr. Drug Metab.* 8:185–94
45. Takagi S, Nakajima M, Mohri T, Yokoi T. 2008. Post-transcriptional regulation of human pregnane X receptor by microRNA affects the expression of cytochrome P450 3A4. *J. Biol. Chem.* 283:9674–80
46. Pan YZ, Gao W, Yu AM. 2009. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. *Drug Metab. Dispos.* 37:2112–17
47. Nagpal S, Na S, Rathnachalam R. 2005. Noncalcemic actions of vitamin D receptor ligands. *Endocr. Rev.* 26:662–87
48. Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signaling pathways in cancer: potential for anti-cancer therapeutics. *Nat. Rev. Cancer* 7:684–700
49. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, et al. 2006. Novel patterns of genome rearrangement and their association with survival in breast cancer. *Genome Res.* 16:1465–79
50. de Lyra EC, de Silva IA, Katayama ML, Brentani MM, Nonogaki S, et al. 2006. 25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> serum concentration and breast tissue expression of 1 $\alpha$ -hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. *J. Steroid Biochem. Mol. Biol.* 100:184–92
51. Carlberg C, Polly P. 1998. Gene regulation by vitamin D<sub>3</sub>. *Crit. Rev. Eukaryot. Gene Expr.* 8:19–42
52. Holick MF. 2007. Vitamin D deficiency. *N. Engl. J. Med.* 357:266–81
53. Friedrich M, Axt-Flidner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J. 2002. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor  $\alpha$  in breast cancer. *Histochem. J.* 34:35–40
54. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerström G, Hellman P. 2006. 25-Hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. *J. Histochem. Cytochem.* 54:355–61
55. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. 2009. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. *Mol. Pharmacol.* 76:702–9
56. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. 2009. MicroRNA regulates human vitamin D receptor. *Int. J. Cancer* 125:1328–33
57. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc. Natl. Acad. Sci. USA* 103:2257–61
58. Gonzalez FJ. 2008. Regulation of hepatocyte nuclear factor 4 $\alpha$ -mediated transcription. *Drug Metab. Pharmacokinet.* 23:2–7
59. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. 2007. Role of human hepatocyte nuclear factor 4 $\alpha$  in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. *Drug Metab. Pharmacokinet.* 22:287–98
60. Takagi S, Nakajima M, Kida K, Yamaura Y, Fukami T, Yokoi T. 2010. MicroRNAs regulate human hepatocyte nuclear factor 4 $\alpha$ , modulating the expression of metabolic enzymes and cell cycle. *J. Biol. Chem.* 285:4415–22
61. Pikuleva IA. 2006. Cytochrome P450s and cholesterol homeostasis. *Pharmacol. Ther.* 112:761–73
62. Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, et al. 1996. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. *Mol. Cell. Biol.* 16:5221–31
63. Choi H, Chun YS, Kim SW, Kim MS, Park JW. 2006. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. *Mol. Pharmacol.* 70:1664–71
64. Choi H, Chun YS, Shin YJ, Ye SK, Kim MS, Park JW. 2008. Curcumin attenuates cytochrome P450 induction in response to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin by ROS-dependently degrading AhR and ARNT. *Cancer Sci.* 99:2518–24
65. Oda Y, Nakajima M, Mohri T, Takamiya M, Aoki Y, et al. 2012. Aryl hydrocarbon nuclear translocator in human liver is regulated by miR-24. *Toxicol. Appl. Pharmacol.* 260:222–31
66. Adams BD, Furneaux H, White BA. 2007. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor- $\alpha$  (ER $\alpha$ ) and represses ER $\alpha$  messenger RNA and protein expression in breast cancer cell lines. *Mol. Endocrinol.* 21:1132–47
67. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. 2008. MicroRNA-221/222 negatively regulates estrogen receptor  $\alpha$  and is associated with tamoxifen resistance in breast cancer. *J. Biol. Chem.* 283:31079–86

68. Xiong J, Yu D, Wei N, Fu H, Cai T, et al. 2010. An estrogen receptor  $\alpha$  suppressor, microRNA-22, is downregulated in estrogen receptor  $\alpha$ -positive human breast cancer cell lines and clinical samples. *FEBS J.* 277:1684–94
69. Pandey DP, Picard D. 2009. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor  $\alpha$  mRNA. *Mol. Cell. Biol.* 29:3783–90
70. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. 2010. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor  $\alpha$  in breast cancer cells. *Cancer Res.* 70:9175–84
71. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, Safe S. 2010. MicroRNA-27a indirectly regulates estrogen receptor  $\alpha$  expression and hormone responsiveness in MCF-7 breast cancer cells. *Endocrinology* 151:2462–73
72. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, et al. 2011. PPAR $\alpha$  is regulated by miR-21 and miR-27b in human liver. *Pharm. Res.* 28:2467–76
73. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, et al. 2009. microRNA miR-27b impairs human adipocyte differentiation and targets PPAR $\gamma$ . *Biochem. Biophys. Res. Commun.* 390:247–51
74. Jennewein C, von Knethen A, Schmid T, Brüne B. 2010. MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) mRNA destabilization. *J. Biol. Chem.* 285:11846–53
75. Kim SY, Kim AY, Lee HW, Son YH, Lee GY, et al. 2010. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPAR $\gamma$  expression. *Biochem. Biophys. Res. Commun.* 392:323–28
76. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. 2009. A role of miR-27 in the regulation of adipogenesis. *FEBS J.* 276:2348–58
77. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. 2009. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. *FEBS Lett.* 583:759–66
78. Imai T, Jiang M, Chambon P, Metzger D. 2001. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor  $\alpha$  mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. *Proc. Natl. Acad. Sci. USA* 98:224–28
79. Rezen T, Rozman D, Pascussi JM, Monostory K. 2011. Interplay between cholesterol and drug metabolism. *Biochim. Biophys. Acta* 1814:146–60
80. Liu X, Yu J, Jiang L, Wang A, Shi F, et al. 2009. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. *Cancer Genomics Proteomics* 6:131–39
81. Xu Y, Fang F, Zhang J, Josson S, St. Clair WH, St. Clair DK. 2010. mir-17\* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. *PLoS ONE* 12:e14356
82. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, et al. 2008. Identification of hypoxia-inducible factor-1 $\alpha$  as a novel target for miR-17-92 microRNA cluster. *Cancer Res.* 68:5540–45
83. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. 2007. Peroxisome proliferator-activated receptor  $\alpha$  regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. *Mol. Cell. Biol.* 27:4238–47
84. Aono J, Yanagawa T, Itoh K, Li B, Yoshida H, et al. 2003. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. *Biochem. Biophys. Res. Commun.* 305:271–77
85. Marsit CJ, Eddy K, Kelsey KT. 2006. MicroRNA responses to cellular stress. *Cancer Res.* 66:10843–48
86. Fukushima T, Hamada Y, Yamada H, Horii I. 2007. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride: regulating role of micro-RNA for RNA expression. *J. Toxicol. Sci.* 32:401–9
87. Izzotti A, Larghero P, Longobardi M, Cartiglia C, Camoirano A, et al. 2011. Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. *Mutat. Res.* 717:9–16
88. Schembri F, Sridhar S, Perdomo C, Gustafson AM, Zhang X, et al. 2009. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. *Proc. Natl. Acad. Sci. USA* 106:2319–24
89. Moffat ID, Boutros PC, Celius T, Lindén J, Pohjanvirta R, Okey AB. 2007. microRNAs in adult rodent liver are refractory to dioxin treatment. *Toxicol. Sci.* 99:470–87

90. Yoshioka W, Higashiyama W, Tohyama C. 2011. Involvement of microRNAs in dioxin-induced liver damage in the mouse. *Toxicol. Sci.* 122:457–65
91. Yauk CL, Jackson K, Malowany M, Williams A. 2011. Lack of change in microRNA expression in adult mouse liver following treatment with benzo(a)pyrene despite robust mRNA transcriptional response. *Mutat. Res.* 722:131–39
92. Malik AI, Williams A, Lemieux CL, White PA, Yauk CL. 2012. Hepatic mRNA, microRNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. *Environ. Mol. Mutagen.* 53:10–21
93. Halappanavar S, Wu D, Williams A, Kuo B, Godschalk RW, et al. 2011. Pulmonary gene and microRNA expression changes in mice exposed to benzo(a)pyrene by oral gavage. *Toxicology* 285:133–41
94. Li D, Wang Q, Liu C, Duan H, Zeng X, et al. 2012. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. *Toxicol. Sci.* 125:382–91
95. Pohjanvirta R, Tuomisto J. 1994. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models. *Pharmacol. Rev.* 46:483–549
96. Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. 2012. miRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. *Cell Cycle* 11:1273–81
97. Chen T, Heflich RH, Moore MM, Mei N. 2010. Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. *Environ. Mol. Mutagen.* 51:156–63
98. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. *Nature* 350:429–31
99. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. 2007. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. *Mutat. Res.* 619:30–37
100. Murakami T, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* 25:2537–45
101. Zhang B, Pan X. 2009. RDX induces aberrant expression microRNAs in mouse brain and liver. *Environ. Health Perspect.* 117:231–40
102. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. 2011. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. *Mutat. Res.* 717:77–84
103. Chen T, Huang Z, Wang L, Wang Y, Wu F, et al. 2009. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. *Cardiovasc. Res.* 83:131–39
104. Braconi C, Huang N, Patel T. 2010. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. *Hepatology* 51:881–90
105. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, et al. 2009. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. *Circ. Res.* 104:1184–91
106. Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, et al. 2007. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. *Blood* 110:1330–33
107. Nahid MA, Pauley KM, Satoh M, Chan EK. 2009. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. *J. Biol. Chem.* 284:34590–99
108. Nahid MA, Satoh M, Chan EK. 2011. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. *J. Immunol.* 186:1723–34
109. Sun Y, Varambally S, Maher CA, Cao Q, Chockley P, et al. 2012. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. *Blood* 117:6172–83
110. Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2009. Halothane-induced liver injury is mediated by interleukin-17 in mice. *Toxicol. Sci.* 111:302–10
111. Kobayashi M, Higuchi S, Mizuno K, Tsuneyama K, Fukami T, et al. 2010. Interleukin-17 is involved in  $\alpha$ -naphthylisothiocyanate-induced liver injury in mice. *Toxicology* 275:50–57
112. Yano A, Higuchi S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2012. Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. *Toxicology* 293:107–14



113. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, et al. 1993. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. *Mol. Pharmacol.* 44:707-15
114. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, et al. 2000. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. *Biochem. Biophys. Res. Commun.* 274:707-13
115. Higuchi S, Kobayashi M, Yano A, Tsuneyama K, Fukami T, et al. 2012. Involvement of Th2 cytokines in the mouse model of flutamide-induced liver injury. *J. Appl. Toxicol.* 32:815-22
116. Higuchi S, Kobayashi M, Yoshikawa Y, Tsuneyama K, Fukami T, et al. 2011. IL-4 mediates dicloxacillin-induced liver injury in mice. *Toxicol. Lett.* 200:139-45
117. Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. 2003. SNP and haplotype variation in the human genome. *Mutat. Res.* 526:53-61
118. Iwai N, Naraba H. 2005. Polymorphisms in human pre-miRNAs. *Biochem. Biophys. Res. Commun.* 331:1439-44
119. Duan R, Pak C, Jin P. 2007. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. *Hum. Mol. Genet.* 16:1124-31
120. Saunders MA, Liang H, Li WH. 2007. Human polymorphism at microRNAs and microRNA target sites. *Proc. Natl. Acad. Sci. USA* 104:3300-5
121. Boni V, Zarate R, Bandrés E, Gomez MA, Maiello E, et al. 2011. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. *Pharmacogenomics J.* 11:429-36
122. Sethupathy P, Collins FS. 2008. MicroRNA target site polymorphisms and human disease. *Trends Genet.* 24:489-97
123. Mishra PJ, Bertino JR. 2009. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. *Pharmacogenomics* 10:399-416
124. Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, et al. 2010. Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (*SULT1A1*) and their effect on enzymatic activity. *Toxicol. Sci.* 118:391-403
125. Richardson K, Lai CQ, Parnell LD, Lee YC, Ordovas JM. 2011. A genome-wide survey for SNPs altering microRNA seed sites identifies functional candidates in GWAS. *BMC Genomics* 12:504
126. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GA, Banerjee D, Bertino JR. 2007. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. *Proc. Natl. Acad. Sci. USA* 104:13513-18
127. Deleted in proof
128. Sun C, Southard C, Olopade OI, Di Rienzo AD. 2011. Differential allelic expression of c.1568C>A at *UGT2B15* is due to variation in a novel *cis*-regulatory element in the 3'UTR. *Gene* 481:24-28
129. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmüller J, et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc. Natl. Acad. Sci. USA* 97:3473-78
130. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. 2008. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br. J. Haematol.* 141:672-75
131. Etheridge A, Lee I, Hood L, Galas D, Wang K. 2011. Extracellular microRNA: a new source of biomarkers. *Mutat. Res.* 717:85-90
132. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. *Proc. Natl. Acad. Sci. USA* 106:4402-7
133. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. 2009. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. *Clin. Chem.* 55:1977-83
134. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. 2010. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. *Clin. Chem.* 56:1830-38
135. Yamaura Y, Nakajima M, Takagi S, Fukami T, Tsuneyama K, Yokoi T. 2012. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. *PLoS ONE* 7:e30250

136. Yang X, Greenhaw J, Shi Q, Su Z, Qian F, et al. 2012. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. *Toxicol. Sci.* 125:335–44
137. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, et al. 2011. Circulating microRNAs as potential markers of human drug-induced liver injury. *Hepatology* 54:1767–76
138. Vreugdenhil E, Verissimo CS, Mariman R, Kamphorst JT, Barbosa JS, et al. 2009. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. *Endocrinology* 150:2220–28
139. Yang M, Yao Y, Eades G, Zhang Y, Zhou Q. 2011. miR-28 regulates Nrf2 expression through a Keap1-independent mechanism. *Breast Cancer Res. Treat.* 129:983–91
140. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. 2011. miR-200a regulates Nrf2 activation by targeting *Keap1* mRNA in breast cancer cells. *J. Biol. Chem.* 286:40725–33

## Review

# The Emerging Role of Human Esterases

Tatsuki FUKAMI\* and Tsuyoshi YOKOI

*Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan*

Full text of this paper is available at <http://www.jstage.jst.go.jp/browse/dmpk>

**Summary:** In this review, novel aspects of the role of esterases, which contribute to the metabolism of 10% of therapeutic drugs, are described. Esterases hydrolyze the compounds that contain ester, amide, and thioester bonds, which cause prodrug activation or detoxification. Among esterases, carboxylesterases are well known to be involved in the hydrolysis of a variety of drugs. Additionally, other esterases have recently received attention for their pharmacological and toxicological roles. Arylacetamide deacetylase (AADAC) is involved in the hydrolysis of flutamide, phenacetin, and rifamycins. AADAC is associated with adverse drug reactions because the hydrolytic metabolites of flutamide and phenacetin appear to be associated with hepatotoxicity and nephrotoxicity/hematotoxicity, respectively. Paraoxonase and butyrylcholinesterase hydrolyze pirocarpine/simvastatin and succinylcholine/bambuterol, respectively. Although the esterases that hydrolyze the acyl-glucuronides of drugs have largely been unknown, we recently found that  $\alpha/\beta$  hydrolase domain containing 10 (ABHD10) is responsible for the hydrolysis of mycophenolic acid acyl-glucuronide in human liver. Because acyl-glucuronides are associated with toxicity, ABHD10 might function as a detoxification enzyme. Thus, various esterases, which include enzymes that have not been known to hydrolyze drugs, are involved in drug metabolism with different substrate specificity. Further esterase studies should be conducted to promote our understanding in clinical pharmacotherapy and drug development.

**Keywords:** esterases; drug hydrolysis; activation of prodrugs; drug detoxification; drug adverse reaction

### Introduction

Drug metabolism refers to the biochemical transformation of a compound into its more polar chemical form. Drug-metabolizing enzymes are responsible for the detoxification of many drugs and xenobiotics to facilitate their excretion, which is an important determinant of drug action. Drug metabolism is classified into phase I and phase II reactions. Phase I metabolism usually results in a change in molecular weight or water solubility of the substrate, and its reactions confer the sites at which phase II metabolism occurs. Phase II conjugation causes an appreciable increase in substrate molecular weight and water solubility. Of the enzymes involved in phase I reactions, cytochrome P450 enzymes play a pivotal role in drug metabolism (*i.e.*, approximately 75% of clinically used drugs), followed by esterases, which contribute to the metabolism of 10% of the clinical, therapeutic drugs that contain ester, amide, and thioester bonds.<sup>1)</sup>

Esterases are responsible for prodrug activation and drug detoxification and have been divided into 3 categories (A-, B-, and C-esterases) based on substrate specificity and sensitivity to various inhibitors (*i.e.*, organophosphates and sulfhydryl reagents). A-esterases rapidly hydrolyze aromatic esters, which include organophosphate diisopropyl fluorophosphates (DFP). The representative A-esterase enzyme is paraoxonase (PON). B-esterases are inhibited by organophosphates, carbamate, and organosulfur compounds. In humans, most esterases, such as carboxylesterases (CESs) and cholinesterases, are B-esterases and members of the serine esterase superfamily that possess a serine residue in the conserved -Gly-X-Ser-X-Gly- motif at the active site. C-esterases neither hydrolyze organophosphate esters nor are inhibited by them. To our knowledge, the C-esterases that likely hydrolyze drugs have not been identified. Nowadays, the above classification is not generally applicable because the function of each esterase has been clarified.

Received April 26, 2012; Accepted July 8, 2012

J-STAGE Advance Published Date: July 17, 2012, doi:10.2133/dmpk.DMPK-12-RV-042

\*To whom correspondence should be addressed: Tatsuki FUKAMI, Ph.D., Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Tel. +81-76-234-4438, Fax. +81-76-234-4407, E-mail: tatsuki@p.kanazawa-u.ac.jp

The authors' studies were supported by a Grant-in-Aid for Young Scientists (B) and a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science.

**Table 1. Summary of esterases responsible for drug metabolism**

Enzyme		EC number	Expressed tissue	Representative substrate drug
CES1	Carboxylesterase 1	EC3.1.1.1 EC3.1.1.56	Liver, lung	Capecitabine, clopidogrel, imidapril, methylphenidate, oseltamivir
CES2	Carboxylesterase 2	EC3.1.1.1 EC3.1.1.56 EC3.1.1.84	Liver, small intestine, kidney	CPT-11, flutamide, heroin, prasugrel
AADAC	Arylacetamide deacetylase	EC3.1.1.3	Liver, small intestine	Flutamide, phenacetin, rifampicin, rifabutin, rifapentine
BCHE	Butyrylcholinesterase	EC3.1.1.8	Liver, plasma	Bambuterol, cocaine, CPT-11, mivacurium, succinylcholine
PON1	Paraoxonase 1	EC3.1.1.2 EC3.1.1.81 EC3.1.8.1	Liver, plasma	Olmesartan medoxomil, pilocarpine, prulifloxacin
PON3	Paraoxonase 3	EC3.1.1.2 EC3.1.1.81 EC3.1.8.1	Liver, plasma	Lovastatin, simvastatin, spironolactone
ABHD10	$\alpha/\beta$ Hydrolase domain containing 10	EC3.4.-.-	Liver, small intestine	Mycophenolic acid acyl-glucuronide
APEH	Acylpeptide hydrolase	EC3.4.19.1	Liver	Valproic acid acyl-glucuronide
SIAE	Sialic acid 9-O-acetylerase	EC3.1.1.53	Liver	Alacepril
CMBL	Carboxymethylenebutenolidase homolog	EC3.1.-.- EC3.1.1.45	Liver, kidney, small intestine	Olmesartan medoxomil, faropenem medoxomil, lenampicillin
BPHL	Biphenyl hydrolase-like protein	EC.3.1.-.-	Small intestine, liver, lung	Valacyclovir, valganciclovir
PAFAH	Platelet-activating factor acetylhydrolase	EC3.1.1.47	Erythrocytes	Aspirin
ALDH	Aldehyde dehydrogenase	EC1.2.1.3	Liver	Nitroglycerin
Albumin		EC6.1.1.16	Liver, plasma	Aspirin, ketoprofen acyl-glucuronide

Among these esterases, CES enzymes are well known for their involvement in drug metabolism. Some human esterases other than CES enzymes have also been demonstrated to hydrolyze several drugs. For example, we found that arylacetamide deacetylase (AADAC), which was previously recognized as a lipase, and  $\alpha/\beta$  hydrolase containing (ABHD) 10, whose function was previously unknown, are involved in the hydrolysis of clinical drugs.<sup>2-5</sup> Therefore, recent evidence demonstrates that various esterases are involved in drug metabolism (Table 1). A comprehensive understanding of esterases would be useful in clinical pharmacotherapy and drug development. This review describes the novel aspects of the roles of the enzymes that are responsible for drug hydrolysis.

### Carboxylesterase

CES enzymes are members of the serine esterase superfamily that possesses the serine residue of the conserved -Gly-X-Ser-X-Gly- motif at the active site and are responsible for the hydrolysis of a wide variety of xenobiotic and endogenous compounds. Human CES enzymes are classified into 5 subfamilies: CES1, CES2, CES3, CES4A, and CES5A.<sup>6</sup> The CES1 subfamily is composed of 2 genes, CES1 (a functional gene, previously termed CES1A1) and CES1P1 (a pseudogene, previously termed CES1A3). Previously, another functional CES1 gene (previously termed CES1A2) was reported to be located at the locus that corresponds to the CES1P1 gene, but our later study determined it to be a CES1P1 variant.<sup>7</sup> The other human CES subfamilies are composed of the corresponding single gene. CES1 and CES2 are reported to be responsible for the biotransforma-

tion of a number of clinically used drugs and prodrugs. CES1 is predominantly expressed in the human liver and marginally expressed in the gastrointestinal tract.<sup>8</sup> The monomeric molecular weight of CES1 is 60 kDa, and CES1 is present as a 180-kDa trimer.<sup>9</sup> CES2 is expressed in the liver as well as in extrahepatic tissues, such as the gastrointestinal tract and kidney.<sup>10</sup> In contrast to CES1, CES2 is a 60-kDa monomer.<sup>11</sup> These CES enzymes contain a hydrophobic signal peptide at the N-terminus for trafficking through the endoplasmic reticulum and a retention sequence at the C-terminus for interacting with the Lys-Asp-Glu-Leu (KDEL) receptor. Therefore, it has been hypothesized that CES enzymes are specifically localized in the lumen side of the endoplasmic reticulum.<sup>12</sup> However, CES1 and CES2 enzymes are also present in human liver cytosol at comparable levels; although, it is unclear whether cytosolic CESs initially possess no signal peptide, the signal peptide had been removed before CESs move to the endoplasmic reticulum, or CESs in endoplasmic reticulum move to the cytosol.<sup>10,13</sup>

Although the amino acid homology of CES1 and CES2 around a serine residue in an active site is high, they exhibit significant differences in their substrate specificity. Clinical drugs such as imidapril, methylphenidate, oseltamivir, and clopidogrel are specifically hydrolyzed by human CES1.<sup>14-17</sup> Capecitabine and oxybutinin are hydrolyzed by CES1 but are also hydrolyzed by CES2 to a minor extent.<sup>18,19</sup> CPT-11 and prasugrel are preferentially hydrolyzed by CES2.<sup>20,21</sup> A small alcohol group and large acyl group are common features of CES1 substrates, except for oxybutinin, whereas CES2 substrates have a large alcohol group and small acyl group (Table 1).

The hydrolysis of drugs that are catalyzed by CES enzymes exhibits large interindividual variability,<sup>17)</sup> which may be due to quantitative and qualitative differences in the CES enzymes. Our previous study reported that CES1 protein expression exhibited approximately 22-fold and 58-fold differences in microsomes and cytosol, respectively, among 12 human livers.<sup>7)</sup> Xu *et al.* reported that the CES2 protein expression exhibited 3-fold and 15-fold differences in microsomes and cytosol, respectively, among 12 human livers.<sup>10)</sup> Two single nucleotide polymorphisms (SNPs) of g.9486G>A and g.12754T>del were found to be associated with an increased area under the blood concentration time curve (AUC) of methylphenidate.<sup>22)</sup> The former SNP leads to an amino acid substitution of G143Q, and the latter causes a frameshift at codon 260 that leads to 39 altered residues and a subsequent premature stop codon. These mutations were also reported to be a causal factor of defective trandolapril hydrolase activity.<sup>23)</sup> In CES2, amino acid substitutions of R34W and V142M have been reported to lose CPT-11 hydrolase activity.<sup>24)</sup> Therefore, a large degree of interindividual variability of CES enzymes is due to the differences in CES expression levels as well as genetic polymorphisms.

To examine the possibility of drug-drug interactions that are caused by CES inhibition, we previously investigated the effects of 11 antidiabetic or 12 antihyperlipidemic drugs on the hydrolase activity of imidapril, which is a CES1-specific substrate, using a recombinant enzyme and human liver microsomes (HLM).<sup>25)</sup> Angiotensin-converting-enzyme (ACE) inhibitors, such as imidapril and derapril, which are substrates of CES enzymes, are often coadministered with various antidiabetic or antihyperlipidemic drugs in clinical pharmacotherapy. The imidapril hydrolase activity by CES1 was strongly inhibited by lactone ring-containing statins, such as simvastatin and lovastatin, and thiazolidinediones, such as troglitazone and rosiglitazone, but the inhibitory potency would not be significant *in vivo* because the maximum free concentrations of these inhibitors at the inlet to the liver are lower than the  $K_i$  values. Therefore, drug-drug interactions *via* CES enzymes may be rare in humans.

In drug development, species differences in enzyme activity, substrate specificity, and tissue distribution require attention. Ces enzymes in the mouse and rat are divided into 5 Ces subfamilies that are similar to human CES enzymes. However, different from human, the Ces1 and Ces2 subfamilies include 8 (Ces1a–Ces1h) and 8 (Ces2a–Ces2h) enzymes in mouse and 5 (Ces1a–Ces1f) and 7 (Ces2a–Ces2j) enzymes in rat.<sup>6)</sup> It was reported that one of the Ces1 enzymes, Ces1c, does not contain an ER-lumen retention sequence at the C-terminus, which would cause secretion into the plasma.<sup>26)</sup> Ces enzyme is present in the plasma of mice, rats, rabbits, horses, cats, and tigers, but not of humans.<sup>27)</sup> The pharmacokinetic profile for irinotecan in Ces1c-deficient mice closely reflects that observed in humans.<sup>28)</sup> Additionally, the difference in substrate specific-


ity of CES enzymes between human and experimental animals has also been reported. For example, pranlukast, which is a leukotriene receptor antagonist, is efficiently hydrolyzed by rat Ces enzymes that are expressed in the liver, but it is not hydrolyzed by human CES enzymes.<sup>29)</sup> Because the substrate specificity of each CES enzyme in various species is not well known, further elucidation will be required.

### Arylacetamide Deacetylase

Human arylacetamide deacetylase (AADAC), which has a molecular weight of 45 kDa, is a microsomal serine esterase that is expressed in the liver and gastrointestinal tissues.<sup>2)</sup> There is a single AADAC isoform in humans and other mammals. Unlike CES enzymes, AADAC is a type II membrane protein that has an uncleaved N-terminal signal anchor sequence to retain on the lumen side of the endoplasmic reticulum.<sup>30)</sup> AADAC was first identified as the enzyme that catalyzes the deacetylation of the carcinogen 2-acetylaminofluorene.<sup>31)</sup> Although 2-acetylaminofluorene is a metabolite of aminofluorene, which is catalyzed by *N*-acetyltransferase (NAT), the acetyl metabolites of other known NAT substrates, such as sulfamethazine, *p*-aminobenzoic acid, procainamide, and *p*-aminosalicylic acid, are not hydrolyzed by AADAC.<sup>31)</sup> In addition to 2-acetylaminofluorene hydrolysis, AADAC has been recognized as a lipase because the active site of AADAC has strong homology with that of hormone-sensitive lipase.<sup>32)</sup> In fact, human AADAC was proven capable of hydrolyzing cholesterol ester when expressed in yeast.<sup>33)</sup>

Recently, we found that human AADAC is responsible for the hydrolysis of clinical drugs, such as flutamide, phenacetin, and rifamycins (Table 1).<sup>2,4)</sup> The clinical significance of AADAC in the hydrolysis of these drugs is described below in detail. Flutamide is a nonsteroidal antiandrogen drug that is used for the treatment of prostate cancer. It occasionally causes severe hepatotoxicity.<sup>34)</sup> Flutamide itself is not toxic when used at the appropriate clinical dose, but bioactivation of flutamide has been considered the cause of flutamide-induced hepatotoxicity.<sup>35)</sup> Flutamide is mainly metabolized to 2-hydroxyflutamide, which is associated with the therapeutic effect, by human CYP1A2<sup>36)</sup> and is also hydrolyzed to 4-nitro-3-(trifluoromethyl)phenylamine (FLU-1)<sup>36,37)</sup> (Fig. 1A) by AADAC and CES2.<sup>2,38)</sup> FLU-1 is an arylamine, whose *N*-hydroxylation is generally recognized to be associated with toxicity.<sup>39)</sup> In fact, several studies have suggested that flutamide-induced hepatotoxicity was caused by *N*-hydroxyl FLU-1, a metabolite of FLU-1 whose formation is catalyzed by CYP3A or CYP1A.<sup>40–42)</sup> Therefore, the hydrolysis of flutamide by AADAC and CES2 is the initial step that leads to hepatotoxicity.

Phenacetin had been widely used as an analgesic antipyretic drug, but it was withdrawn from the market because of the occurrence of renal failure and hematotoxicity in some patients.<sup>43,44)</sup> Phenacetin is mainly metabolized to



**Fig. 1. Metabolic pathways of flutamide and phenacetin in humans**

(A) Flutamide and (B) phenacetin are metabolized to pharmacologically active metabolites by CYP1A2. Their hydrolysis by AADAC leads to the formation of toxic metabolites.

acetaminophen, which is a pharmacologically active metabolite, by CYP1A2 and is hydrolyzed to *p*-phenetidine by AADAC (Fig. 1B). *p*-Phenetidine is further metabolized to *N*-hydroxyphenetidine, which has been considered to cause renal failure and hematotoxicity, such as methemoglobinemia and hemolytic anemia.<sup>45–47</sup> An *in vitro* analysis demonstrated that phenacetin-induced methemoglobinemia is caused by a hydrolytic metabolite which is formed by AADAC, and subsequent hydroxylation by CYP2E1 or CYP1A2.<sup>48</sup> *p*-Phenetidine is an arylamine, likely FLU-1. Therefore, because AADAC produces arylamines from *N*-acetylarylamines, this would cause toxic effects.

Rifamycins, such as rifampicin, rifabutin, and rifapentine, are a group of structurally similar, complex macrocyclic antibiotics that are produced by *Streptomyces mediterranei* and are important first-line antituberculosis drugs. The main metabolic pathway is 25-deacetylation by AADAC. Rifamycins are known to induce various drug-metabolizing enzymes, such as CYP3A4, but 25-deacetyl rifamycins have no or little induction potency.<sup>4</sup> Rifampicin has been reported to cause toxic injury to hepatocytes.<sup>49</sup> However, we found that 25-desacetyl rifamycins exhibit no or less cytotoxicity compared with the parent rifamycins.<sup>4</sup> Therefore, human AADAC would mediate decreasing the induction rates of drug-metabolizing enzymes and hepatotoxicity

by rifamycins.

The common characteristics in the abovementioned AADAC substrates are that they contain a large alcohol group and small acyl group, which is similar to CES2 substrates. In fact, both AADAC and CES2 have been shown to be involved in flutamide hydrolysis in the human liver at low and high concentrations of flutamide, respectively.<sup>38</sup> However, phenacetin and rifamycins are not hydrolyzed by CES2. An understanding of the substrate specificity differences between AADAC and CES2 is of interest.

When we measured flutamide hydrolase activity at 500  $\mu\text{M}$ , at which concentration AADAC is predominantly contributed to flutamide hydrolysis, a 50-fold interindividual variability was observed in microsomes from 24 human livers.<sup>50</sup> Similarly, 22- and 205-fold interindividual variabilities in the hydrolase activities of phenacetin (1 mM) and rifampicin (50  $\mu\text{M}$ ), respectively, were observed.<sup>50</sup> Our recent study found a polymorphic mutation in the AADAC gene that caused diminished enzyme activity from a human liver sample with remarkably low flutamide hydrolase activity.<sup>50</sup> This allele possesses a SNP of g.14008T>C that causes an amino acid (glutamine) extension at the C-terminus. This allele was found in European-Americans (1.3%) and African-Americans (2.0%), but not in Koreans or Japanese. In the sequence analysis, another SNP, g.13651G>A (V281I), was also found in the four abovementioned populations with relatively high frequencies of 49.5–63.5% and does not appear to cause a marked enzyme activity change. Our recent study found that AADAC protein expression exhibited approximately 200-fold differences in the microsomes among 24 human livers.<sup>50</sup> Because these polymorphic alleles alone could not account for the interindividual variability, further investigation of the mechanisms that affect their expression levels is required.

The species differences in the enzyme activity, substrate specificity, and tissue distribution of AADAC were evaluated using humans and rodents (mouse and rat samples).<sup>51</sup> AADAC mRNA is highly expressed in the liver as well as in the gastrointestinal tract in humans, whereas AADAC mRNA is expressed in the liver at the highest level, followed by the gastrointestinal tract (jejunum) and kidney in rodents. Recombinant mouse and rat AADAC proteins exhibited the hydrolase activities of flutamide and phenacetin but not rifampicin. In support of this finding, rodent liver microsomes did not exhibit rifampicin hydrolase activity. It was reported that 25-deacetyl rifampicin was detected in human plasma as the principal metabolite, whereas it was barely detected in rat and rabbit plasma.<sup>52,53</sup> Additionally, it was reported that dog tissues were also unable to hydrolyze rifampicin.<sup>54</sup> Therefore, 25-deacetyl rifampicin is likely a specific metabolite formed by human AADAC. Species differences in AADAC substrate specificity should receive attention during the preclinical drug development process.

## Cholinesterase

In human cholinesterases, there are 2 principal enzymes: acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE).<sup>55</sup> ACHE is predominantly expressed in the tissues, such as brain and muscles, and erythrocytes. ACHE in tissues and erythrocytes possesses a large common catalytic domain but has a different C-terminal sequence that is produced by alternative splicing.<sup>56</sup> ACHE exists as polymers of catalytic subunits.<sup>57</sup> The globular forms, G1, G2, and G4, contain 1, 2, or 4 subunits, respectively. The asymmetric form, A12, contains 12 subunits. ACHE is involved in the acceleration of amyloid formation, which is associated with Alzheimer's disease in the brain. Therefore, for the treatment of Alzheimer's disease, several ACHE inhibitors, such as donepezil and rivastigmine, are used.<sup>58</sup> However, knowledge concerning drugs that are hydrolyzed by ACHE is limited.

BCHE is expressed in the liver, lung, brain, and heart tissues.<sup>59</sup> BCHE is predominantly present in plasma because BCHE that is synthesized in the liver is secreted into the plasma. BCHE has similar catalytic properties to ACHE. The G4 tetramer constitutes the majority of the plasma BCHE.<sup>60</sup> In contrast to ACHE, several drugs have been reported to be substrates of BCHE. The neuromuscular blocking agents, such as succinylcholine and mivacurium, are predominantly hydrolyzed by BCHE. Low plasma BCHE enzyme activity, which is caused by organophosphate poisoning and BCHE genetic polymorphisms, in patients is associated with prolonged apnea following clinical exposure to succinylcholine and mivacurium.<sup>61–63</sup> Bambuterol, which is a  $\beta$ -adrenoceptor agonist that is used for the treatment of asthma, is hydrolyzed primarily by BCHE to terbutaline, which is a pharmaceutically active metabolite. Bambuterol has the potency to inhibit BCHE enzyme activity, resulting in the slow conversion of bambuterol to terbutaline. This can explain the long acting feature of bambuterol.

Cocaine, which is a stimulant of the central nervous system, an appetite suppressant, and a topical anesthetic, contains 2 ester bonds and is hydrolyzed to ecgonine methyl ester and benzoylecgonine.<sup>64</sup> The ecgonine methyl ester, which is a major metabolite found in urine, is formed by hydrolysis by BCHE. However, in tissues, CES2 can also catalyze this hydrolysis reaction.<sup>11</sup> The relative contribution of these enzymes to ecgonine methyl ester formation is unknown. A second metabolite, benzoylecgonine, which is found in urine, is produced by the cleavage of another ester bond by CES1 in human liver. Therefore, cocaine is hydrolyzed by multiple esterases to produce 2 metabolites.

CPT-11 is known to be hydrolyzed by CES and BCHE enzymes.<sup>65</sup> The  $K_m$  value of CPT-11 hydrolysis by human BCHE is  $42.4 \pm 10.6 \mu\text{M}$ , which is higher than that by human CES2 ( $3.4 \pm 1.4 \mu\text{M}$ ).<sup>20</sup> BCHE is predominantly expressed in human plasma, whereas CES enzymes are expressed in human tissues, such as the liver and intestine.


The contribution of human BCHE to the hydrolysis of CPT-11 is unclear.

## Paraoxonase

Different from esterases described above, paraoxonases (PONs) do not belong to the serine esterase family and require calcium to exert their activities and stabilities.<sup>66</sup> The human PON family consists of three isoforms, PON1, PON2, and PON3, in which the gene loci are adjacent on the long arm of chromosome 7q21.3–22.1.<sup>67</sup> These genes are approximately 65% homologous at the amino acid level and have similar molecular weights (43–45 kDa).<sup>67</sup> In mammals, 3 PON isoforms are well conserved; PON orthologs share greater than 80% amino acid homology.<sup>67,68</sup> It has been reported that PON1 and PON3 are synthesized primarily in the liver and partially secreted into the plasma, whereas PON2 is ubiquitously expressed in human tissues except plasma.<sup>69</sup> In the liver, PON enzymes are mainly localized in the endoplasmic reticulum.<sup>70</sup> PON enzymes are considered to be luminal endoplasmic reticulum proteins, because they have one disulfide bridge between Cys residues, which would favor a luminal protein orientation. In plasma, PON1 resides on the high-density lipoprotein (HDL) cholesterol-carrying particles. Apolipoprotein A-I, which is the major structural protein on HDL, appears to interact with PON1, to make PON1 highly stable and an active conformation.<sup>71</sup>

PON1 hydrolyzes organophosphates, such as paraoxon, sarin, and soman.<sup>72,73</sup> In drug metabolism, PON1 hydrolyzes lactone- or cyclic carbonate-containing drugs, such as prulifloxacin,<sup>74</sup> pilocarpine,<sup>75</sup> and olmesartan medoxomil.<sup>76</sup> Pilocarpine hydrolysis causes pharmacological inactivation, whereas prulifloxacin and olmesartan medoxomil hydrolysis causes pharmacological activation. PON enzymes exhibit a calcium-dependent activity at calcium concentrations of 0–10  $\mu\text{M}$  and a maximum activity at a 20- $\mu\text{M}$  calcium concentration.<sup>66</sup> The plasma calcium concentration is normally 1 mM.<sup>66</sup> In contrast, the calcium concentration in the endoplasmic reticulum in the liver is normally 0.1 to 1  $\mu\text{M}$ .<sup>66</sup> Therefore, PON could exert enzyme activity in human liver, although the activity in plasma might be higher compared with that in human liver.

PON1 has 2 common polymorphisms, L55M and Q192R. The effects of the amino acid substitution of Q192R are substrate dependent. For example, paraoxon is more efficiently hydrolyzed by PON1 192R, but soman and sarin are more efficiently hydrolyzed by 192Q.<sup>77</sup> In drug metabolism, we previously investigated the effect of PON1 Q192R on pilocarpine hydrolysis (Fig. 2).<sup>75</sup> Figure 2B represents the pilocarpine hydrolase activity in 50 individual human plasma samples with different *PON1* genotypes. The activities in the plasma of 192R homozygote subjects were significantly higher than those in the plasma of subjects with the 192Q polymorphism. This result was not changed by correcting the pilocarpine hydrolase activity with phenyl acetate



**Fig. 2. The effects of PON1 polymorphisms (Q192R) on the pilocarpine hydrolysis activity in human plasma**

(A) Metabolic pathways of pilocarpine in humans. Pilocarpine is metabolized to pilocarpic acid by PON1 and 3-hydroxypilocarpine by CYP2A6. These metabolites are detected in human blood and excreted into the urine at a level approximately equal to that of the parent drug pilocarpine after oral administration. Pilocarpine hydrolysis activities in human plasma with different PON1 genotypes are presented with (B) raw data and (C) corrected data with the phenyl acetate hydrolysis activities. Phenyl acetate hydrolysis activity was used as a PON1 expression index because it was reported that the PON1 Q192R polymorphism does not affect phenyl acetate hydrolysis activity. Human plasma samples from 50 Japanese subjects were used. Seven, 20, and 23 subjects were genotyped as 192Q/Q, 192Q/R, and 192R/R, respectively. Pilocarpine hydrolysis activities in plasma were determined at a substrate concentration of 3 mM. \* $p < 0.05$  compared with 192Q/Q; # $p < 0.05$ ; ## $p < 0.005$  compared with 192Q/R.

hydrolysis activity, which has been reported to be unaffected by the PON1 Q192R polymorphism (Fig. 2C). Additionally, the catalytic efficiency of recombinant PON1 192R was significantly higher compared with that of recombinant PON1 192Q.<sup>75</sup> Therefore, we found that pilocarpine hydrolysis is more efficiently catalyzed by PON1 192R. The catalytic efficiency of olmesartan medoxomil by PON1 192R has been reported to also be higher compared with that by PON1 192Q.<sup>76</sup> The allele frequency of PON1 Q192R differs by ethnic group as follows: 63%, 60%, and 26% in African-Americans, Asians (Japanese), and Caucasians, respectively.<sup>78–80</sup> The amino acid substitution of L55M unlikely affects catalytic activity, but PON1 55M is associated with decreased PON1 protein levels in plasma.<sup>81,82</sup> This would be because of a strong linkage disequilibrium

with g. –108T>C in the promoter region.<sup>83</sup> In the development of PON1-hydrolyzed drugs, taking note of the PON1 genetic polymorphisms may be required.

The only known substrate of PON2 is *N*-(3-oxododecanoyl)-L-homoserine lactone, which is a key auto-inducer that is synthesized by *Pseudomonas aeruginosa*.<sup>84</sup> To date, no PON2-hydrolyzed drugs have been reported.


PON3 is capable of hydrolyzing lovastatin, simvastatin, and spironolactone, which contain a lactone ring.<sup>85</sup> Although pilocarpine also contains a lactone ring, it cannot be hydrolyzed by PON3.<sup>75</sup> Therefore, PON3 and PON1 can catalyze the hydrolysis of lactone-containing drugs, but the differences in substrate specificity between them are unclear. Several polymorphic mutations in the PON3 gene are known,<sup>86,87</sup> but the effects on drug metabolism have not been determined.

In summary, PON enzymes primarily catalyze lactone ring-containing drugs. PON2 and PON3 are much less studied compared with PON1; therefore, the roles of PON2 and PON3 in drug metabolism require elucidation.

### Esterases Responsible for Deglucuronidation of Acyl-glucuronides

Glucuronidation that is catalyzed by UGT enzymes accounts for the metabolism of more than 35% of all drugs that are metabolized by phase II enzymes.<sup>88</sup> In general, glucuronides are neither active nor reactive and are rapidly excreted from the body.<sup>89</sup> However, it has been reported that acyl-glucuronides, which are formed from compounds that contain carboxylic acid, can bind covalently to proteins and other macromolecules because of their electrophilicity, which suggests that they are associated with immunogenicity and toxicity.<sup>89</sup> The formed glucuronides are primarily hydrolyzed by  $\beta$ -glucuronidase, especially in the gut. However, because acyl-glucuronides contain an ester bond, they may be hydrolyzed by esterases that are expressed in tissues as well as  $\beta$ -glucuronidase. As a drug that forms acyl-glucuronide, we studied mycophenolic acid (MPA). MPA is primarily metabolized to the inactive phenolic glucuronide (MPAG),<sup>90</sup> and partially to MPA acyl-glucuronide (AcMPAG) (Fig. 3A).<sup>91</sup> Although the AcMPAG deglucuronidation was detected in human liver homogenates, the deglucuronidation was not inhibited by D-saccharic acid 1,4-lactone, a  $\beta$ -glucuronidase inhibitor.<sup>5</sup> Our recent study found by purifying the responsible enzyme from human liver cytosol (HLC) that  $\alpha/\beta$  hydrolase domain containing (ABHD) 10 catalyzes the deglucuronidation of AcMPAG.<sup>5</sup> The theoretical molecular weight of human ABHD10 is 34 kDa, but the purified ABHD10 shows a 28-kDa band by Western blotting. According to the National Center for Biotechnology Information database (accession number Q9NUJ1), 52 amino acids on the N-terminal end and the residual 254 amino acids of the human ABHD10 precursor are regarded as the transit peptide and mature chain, respectively. The purified ABHD10 would correspond to the mature form.





**Fig. 3. The role of ABHD10 in the formation of mycophenolic acid acyl-glucuronide in human liver**

(A) Major metabolic pathways of MPA in humans. MPA is metabolized to its phenolic glucuronide (MPAG) and acyl-glucuronide (AcMPAG). AcMPAG deglucuronidation is catalyzed by ABHD10. (B) Kinetic analyses of AcMPAG formation from MPA in human liver homogenates in the presence or absence of 1 mM PMSF, which is an ABHD10 inhibitor. The  $CL_{int}$  value in the presence of PMSF is 1.84-fold higher compared with that in the absence of PMSF. Each data point represents the mean  $\pm$  SD of triplicate determinations. \*\* $p < 0.01$  and \*\*\* $p < 0.001$  compared with the control sample (Student's *t*-test).

Recombinant human ABHD10 could not hydrolyze phenolic glucuronide. ABHD10 is expressed in both of HLM and HLC. The catalytic efficiency of AcMPAG formation in human liver homogenates was increased by phenylmethylsulfonyl fluoride (PMSF), which is an ABHD10 inhibitor (Fig. 3B). It has been reported that AcMPAG promotes the release of TNF- $\alpha$  and IL-6, which are proinflammatory cytokines, from human mononuclear leukocytes.<sup>92)</sup> Additionally, AcMPAG can covalently bind to ATPase/ATP synthetase and protein disulfide isomerase, which are essential for the control of energy and the redox state of cells.<sup>93)</sup> Therefore, because AcMPAG appears to be associated with immunogenicity and toxicity, ABHD10 may function to

protect against the adverse effects of MPA. The substrate specificity of human ABHD10 is under investigation in our laboratory. The human ABHD family consists of 19 isoforms (ABHD1–ABHD11, ABHD12(A), ABHD12B, ABHD13, ABHD14A, ABHD14B, ABHD15, ABHD16A, and ABHD16B), but other than ABHD10, the involvement of ABHD enzymes in drug metabolism remains unknown.

Recently, it was reported that the deglucuronidation of valproic acid acyl-glucuronide in HLC is catalyzed by acylpeptide hydrolase (APEH).<sup>94)</sup> The monomeric molecular weight of APEH is 75 kDa, and APEH is present as a homotetrameric protein (300 kDa).<sup>95)</sup> APEH is originally recognized as the peptidase that catalyzes the hydrolysis of the N-terminus of proteins to release the N-terminal-acetylated amino acid. Information is limited for the involvement of this enzyme in drug metabolism. However, plasma valproic acid concentrations are decreased by concomitant use with carbapenem antibiotics in epileptic patients.<sup>96)</sup> The drug-drug interaction can be explained by the inhibition of APEH by panipenem.

Human serum albumin (HSA) has an esterase-like activity for the deglucuronidation of acyl-glucuronide of fenoprofen, etodolac, ketoprofen, and gemfibrozil.<sup>97–100)</sup> HSA is a major protein in plasma to which various compounds bind.<sup>101)</sup> The reversible binding of acyl-glucuronides to HSA would promote acyl-glucuronide hydrolysis. Additionally, HSA might be a target for forming a covalent adduct of acyl-glucuronide.<sup>102)</sup> To date, the effect of HSA on the formation of acyl-glucuronide in the body is unknown.

Various esterases and proteins catalyze acyl-glucuronide deglucuronidation. Studies of clofibric acid in rabbits and zomepirac in guinea pigs have demonstrated that esterases, rather than  $\beta$ -glucuronidase, are primarily involved in acyl-glucuronide deglucuronidation.<sup>103,104)</sup> Although information for rabbit and guinea pig ABHD10 was not reported, ABHD10 between human and rodents (mouse and rat) share approximately 75% amino acid homology. APEH between human and other animals, such as guinea pigs and rabbits share more than 90% amino acid homology. However, the contribution of these enzymes to the hydrolysis of acyl-glucuronide in animals remains to be clarified. In mice that lack hepatic  $\beta$ -glucuronidase, it was reported that more bilirubin acyl-glucuronides are excreted in bile compared with control mice.<sup>105)</sup> Further study will be required to evaluate the extent to which acyl-glucuronide deglucuronidation of drugs by the abovementioned esterases and proteins have an *in vivo* effect.

### Other Enzymes Responsible for Drug Hydrolysis

This section describes the other esterases for which evidence of involvement in drug hydrolysis is accumulating.

It was reported that sialic acid 9-*O*-acetylcylase (SIAE) enzymes that are expressed in the lysosome and cytosol were encoded by a single gene by different usage of exons at the N-terminus.<sup>106)</sup> Usui *et al.* found that SIAE is an enzyme that

catalyzes the hydrolysis of alacepril by the purification of the responsible enzyme from rat liver cytosol.<sup>107)</sup> However, they suggested that lysosomal SIAE was detected in the cytosol because frozen rat livers were used as the sample material for purification.<sup>107)</sup> It has not been examined whether cytosolic SIAE can hydrolyze alacepril. SIAE cannot hydrolyze other ACE inhibitors, which are classified as dicarboxylate-containing agents, such as imidapril, delapril, and temocapril.<sup>14)</sup> In humans, there are 2 types of SIAEs, lysosomal and cytosolic enzymes, which are similar to rat SIAEs. Human and rat SIAE showed 75% amino acid homology. To date, it is unknown whether human SIAEs can catalyze alacepril.

Olmesartan medoxomil is hydrolyzed by carboxymethyl-enebutenolidase homolog (CMBL) in human tissues, mainly in the liver and intestine cytosol.<sup>108)</sup> As described above, PON1 also efficiently hydrolyzes olmesartan medoxomil to olmesartan in human plasma. Because it was reported that ormesartan alone was detected in plasma after the oral administration of olmesartan medoxomil,<sup>109)</sup> PON1 and CMBL in the small intestine, portal blood, and liver would be highly involved in the hydrolysis of olmesartan medoxomil. CMBL can hydrolyze faropenem medoxomil and lenampicillin, but not prulifloxacin despite their structural similarity. In contrast, PON1 hydrolyzes prulifloxacin, which demonstrates a substrate specificity difference toward CMBL.

Valacyclovir and valganciclovir are amino acid ester prodrugs of acyclovir, which is pharmacologically active. Their oral bioavailabilities are several-fold higher than that of acyclovir.<sup>110)</sup> After absorption from the gut, they are efficiently hydrolyzed to acyclovir. Kim *et al.* demonstrated that one enzyme responsible for the hydrolysis of valacyclovir and valganciclovir is biphenyl hydrolase-like protein (BPHL), which is highly expressed in human intestine, liver, and kidney.<sup>111,112)</sup> The substrate specificity of BPHL resides mainly in the acyl moiety and to a lesser extent in the alcohol moiety.<sup>113)</sup> Considering the chemical structures of valacyclovir and valganciclovir, it is proposed that BPHL should be termed an  $\alpha$ -amino acid ester prodrug-activating enzyme rather than a nucleoside prodrug-activating enzyme. Considering the substrate specificity of BPHL based on the amino acid acyl group,<sup>114)</sup> new prodrugs, especially antiviral and anticancer nucleoside prodrugs, with increased absorption could be developed.

Recently, it was reported that human erythrocytes exhibit more efficient hydrolysis activity of aspirin, a classic nonsteroidal anti-inflammatory agent, rather than human plasma, and identified erythrocyte type I platelet-activating factor acetylhydrolase (PAFAH) as the responsible enzyme in human erythrocytes.<sup>115)</sup> This enzyme exists as a trimer that is composed of homo- or heterodimers of 2 catalytic subunits, either PAFAH1B3 or PAFAH1B2 and a non-catalytic PAFAH1B1 protein subunit. Aspirin ineffectiveness is observed in some individuals. The interindividual varia-

bility of PAFAH enzyme activity might cause this ineffectiveness, although aspirin hydrolysis is catalyzed by other esterases, such as CES2.<sup>14)</sup>

Aldehyde dehydrogenase (ALDH) in human liver, which is widely known to catalyze the oxidation of both aliphatic and aromatic aldehydes to their corresponding carboxylic acids, appears to participate in hydrolysis.<sup>116)</sup> Human ALDH is classified into 11 subfamilies (*i.e.*, ALDH1–ALDH9, ALDH16, and ALDH18). Among them, several enzymes, such as ALDH1A1, ALDH2, and ALDH3A1, can catalyze the hydrolysis of *p*-nitrophenyl acetate.<sup>117,118)</sup> Although there are no reports that human ALDH is involved in the hydrolysis of clinical drugs that contain carboxylic esters, amides, or thioesters, ALDH2, which is localized in mitochondria, plays an important role for the hydrolysis of nitroglycerin, which contains nitroester.<sup>119)</sup> Nitroglycerin hydrolysis generates 1,2-glycerol dinitrate and nitrite (NO<sup>2-</sup>) that is further converted to nitric oxide, which is associated with the treatment of angina pectoris. A polymorphic *ALDH2* mutation is associated with a lack of nitroglycerin efficacy in Chinese patients.<sup>120)</sup>

### Conclusions and Further Prospects

Over time, evidence has accumulated concerning the roles of esterases in drug metabolism. Prodrugs are hydrolytically activated after absorption from the gastrointestinal tract. Conversely, some drugs are hydrolytically inactivated. Additionally, drug hydrolysis is sometimes associated with toxicity. Therefore, esterases play important roles in the regulation of drug efficacy and toxicity.

The differences in the substrate specificities of esterases have not been fully elucidated. In CES enzymes, CES1 prefers substrates with a small alcohol group and large acyl group, whereas CES2 prefers substrates with a large alcohol group and small acyl group. AADAC also prefers substrates with the same characteristics as CES2. BCHE also hydrolyzes the same substrates as CES2. It will be a challenge to clarify the substrate specificity of each esterase. Furthermore, in some cases, the hydrolysis of a drug is catalyzed by more than 2 esterases in various tissues and blood. Predicting the contribution of each esterase to the hydrolysis of drugs in the body is also important.

There are several clinical drugs for which the esterase(s) that are involved in their hydrolysis are unknown. Additionally, there are uncharacterized esterases involved in the hydrolysis of clinical drugs. Unidentified esterase(s) involved in drug metabolism may exist in humans. Further studies of esterases that catalyze the hydrolysis of clinical drugs will facilitate our understanding of the pharmacological and toxicological importance of esterases.

**Acknowledgments:** We thank Dr. Miki Nakajima (Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan) for comments on this manuscript.

## References

- 1) Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. *Drug Metab. Dispos.*, **32**: 1201–1208 (2004).
- 2) Watanabe, A., Fukami, T., Nakajima, M., Takamiya, M., Aoki, Y. and Yokoi, T.: Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. *Drug Metab. Dispos.*, **37**: 1513–1520 (2009).
- 3) Watanabe, A., Fukami, T., Takahashi, S., Kobayashi, Y., Nakagawa, N., Nakajima, M. and Yokoi, T.: Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. *Drug Metab. Dispos.*, **38**: 1532–1537 (2010).
- 4) Nakajima, A., Fukami, T., Kobayashi, Y., Watanabe, A., Nakajima, M. and Yokoi, T.: Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. *Biochem. Pharmacol.*, **82**: 1747–1756 (2011).
- 5) Iwamura, A., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Human  $\alpha/\beta$  hydrolase domain containing 10 (ABHD10) is a responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. *J. Biol. Chem.*, **287**: 9240–9249 (2012).
- 6) Holmes, R. S., Wright, M. W., Laulederkind, S. J., Cox, L. A., Hosokawa, M., Imai, T., Ishibashi, S., Lehner, R., Miyazaki, M., Perkins, E. J., Potter, P. M., Redinbo, M. R., Robert, J., Satoh, T., Yamashita, T., Yan, B., Yokoi, T., Zechner, R. and Maltais, L. J.: Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. *Mamm. Genome*, **21**: 427–441 (2010).
- 7) Fukami, T., Nakajima, M., Maruichi, T., Takahashi, S., Takamiya, M., Aoki, Y., McLeod, H. L. and Yokoi, T.: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. *Pharmacogenet. Genomics*, **18**: 911–920 (2008).
- 8) Imai, T.: Human carboxylesterase isozymes: catalytic properties and rational drug design. *Drug Metab. Pharmacokin.*, **21**: 173–185 (2006).
- 9) Brzezinski, M. R., Abraham, T. L., Stone, C. L., Dean, R. A. and Bosron, W. F.: Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzylecgonine and the formation of cocaethylene from alcohol and cocaine. *Biochem. Pharmacol.*, **48**: 1747–1755 (1994).
- 10) Xu, G., Zhang, W., Ma, M. K. and McLeod, H. L.: Human carboxylesterase 2 is commonly expressed in tumor tissues and is correlated with activation of irinotecan. *Clin. Cancer Res.*, **8**: 2605–2611 (2002).
- 11) Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A. and Bosron, W. F.: Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. *J. Biol. Chem.*, **272**: 14769–14775 (1997).
- 12) Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M. and Danks, M. K.: Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. *Cancer Res.*, **58**: 3627–3632 (1998).
- 13) Tabata, T., Katoh, M., Tokudome, S., Nakajima, M. and Yokoi, T.: Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver. *Drug Metab. Dispos.*, **32**: 1103–1110 (2004).
- 14) Takai, S., Matsuda, A., Usami, Y., Adachi, T., Sugiyama, T., Katagiri, Y., Tatematsu, M. and Hirano, K.: Hydrolytic profile for ester- or amide-linkage by carboxylesterases pl 5.3 and pl 4.5 from human liver. *Biol. Pharm. Bull.*, **20**: 869–873 (1997).
- 15) Sun, Z., Murry, D. J., Sanghani, S. P., Davis, W. I., Kedishvili, N. Y., Zou, Q., Hurley, T. D. and Bosron, W. F.: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. *J. Pharmacol. Exp. Ther.*, **310**: 469–476 (2004).
- 16) Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., You, L., Akhlaghi, F. and Yan, B.: Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. *J. Pharmacol. Exp. Ther.*, **319**: 1477–1484 (2006).
- 17) Tang, M., Mukundan, M., Yang, J., Charpentier, N., LeCluyse, E. L., Black, C., Yang, D., Shi, D. and Yan, B.: Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterified in the presence of ethyl alcohol. *J. Pharmacol. Exp. Ther.*, **319**: 1467–1476 (2006).
- 18) Tabata, T., Katoh, M., Tokudome, S., Hosokawa, M., Chiba, K., Nakajima, M. and Yokoi, T.: Bioactivation of capecitabine in human liver: Involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. *Drug Metab. Dispos.*, **32**: 762–767 (2004).
- 19) Sato, Y., Miyashita, A., Iwatsubo, T. and Usui, T.: Conclusive identification of the oxybutinin-hydrolyzing enzyme in human liver. *Drug Metab. Dispos.*, **40**: 902–906 (2012).
- 20) Humerickhouse, R., Lohrbach, L., Li, L., Bosron, W. F. and Dolan, M. E.: Characterization of irinotecan hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. *Cancer Res.*, **60**: 1189–1192 (2000).
- 21) Williams, E. T., Jones, K. O., Ponsler, G. D., Lowery, S. M., Perkins, E. J., Wrighton, S. A., Ruterbories, K. J., Kazui, M. and Farid, N. A.: The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. *Drug Metab. Dispos.*, **36**: 1227–1232 (2008).
- 22) Zhu, H. J., Patrick, K. S., Yuan, H. J., Wang, J. S., Donovan, J. L., DeVane, C. L., Malcolm, R., Johnson, J. A., Youngblood, G. L., Sweet, D. H., Langae, T. Y. and Markowitz, J. S.: Two CES1 gene mutations lead to dysfunctional carboxylesterase1 activity in man: clinical significance and molecular basis. *Am. J. Hum. Genet.*, **82**: 1241–1248 (2008).
- 23) Zhu, H. J., Appel, D. I., Johnson, J. A., Chavin, K. D. and Markowitz, J. S.: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis oftrandolapril. *Biochem. Pharmacol.*, **77**: 1266–1272 (2009).
- 24) Kubo, T., Kim, S.-R., Sai, K., Saito, Y., Nakajima, T., Matsumoto, K., Saito, H., Shira, K., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Ohno, Y., Ozawa, S. and Sawada, J.-I.: Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). *Drug Metab. Dispos.*, **33**: 1482–1487 (2005).
- 25) Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. and Yokoi, T.: In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. *Drug Metab. Dispos.*, **38**: 2173–2178 (2010).
- 26) Ovnicek, M., Swank, R. T., Fletcher, C., Zhen, L., Novak, E. K., Baumann, H., Heintz, N. and Ganschow, R. E.: Characterization and functional expression of a cDNA encoding egasyn (esterase-22): the endoplasmic reticulum-targeting protein of  $\beta$ -glucuronidase. *Genomics*, **11**: 956–967 (1991).
- 27) Li, B., Sediacek, M., Manoharan, I., Boopathy, R., Duysen, E. G., Masson, P. and Lockridge, O.: Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. *Biochem. Pharmacol.*, **70**: 1673–1684 (2005).
- 28) Morton, C. L., Iacono, L., Hyatt, J. L., Taylor, K. R., Cheshire,

- P. J., Houghton, P. J., Danks, M. K., Stewart, C. F. and Potter, P. M.: Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. *Cancer Chemother. Pharmacol.*, 56: 629–636 (2005).
- 29) Luan, L., Sugiyama, T., Takai, S., Usami, Y., Adachi, T., Katagiri, Y. and Hirano, K.: Purification and characterization of pranlukast hydrolase from rat liver microsomes: the hydrolase is identical to carboxylesterase pl 6.2. *Biol. Pharm. Bull.*, 20: 71–75 (1997).
- 30) Frick, C., Atanasov, A. G., Arnold, P., Ozols, J. and Odermatt, A.: Appropriate function of  $11\beta$ -hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. *J. Biol. Chem.*, 279: 31131–31138 (2004).
- 31) Probst, M. R., Jenö, P. and Meyer, U. A.: Purification and characterization of a human liver arylacetamide deacetylase. *Biochem. Biophys. Res. Commun.*, 177: 453–459 (1991).
- 32) Probst, M. R., Beer, M., Beer, D., Jenö, P., Meyer, U. A. and Gasser, R.: Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylacetamide carcinogens with high sequence similarity to hormone-sensitive lipase. *J. Biol. Chem.*, 269: 21650–21656 (1994).
- 33) Tiwari, R., Koffel, R. and Schneiter, R.: An acetylation/deacetylation cycle controls the export of sterols and steroid from *S. cerevisiae*. *EMBO J.*, 26: 5109–5119 (2007).
- 34) Thole, Z., Manso, G., Salgueiro, E., Revuelta, P. and Hidalgo, A.: Hepatotoxicity induced by antiandrogens: a review of the literature. *Urol. Int.*, 73: 289–295 (2004).
- 35) Fau, D., Eugene, D., Berson, A., Letteron, P., Fromenty, B., Fisch, C. and Pessayre, D.: Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. *J. Pharmacol. Exp. Ther.*, 269: 954–962 (1994).
- 36) Katchen, B. and Buxbaum, S.: Disposition of a new, nonsteroid, antiandrogen,  $\alpha,\alpha,\alpha$ -trifluoro-2-methyl-4'-nitro-*m*-propionotoluidine (Flutamide), in men following a single oral 200 mg dose. *J. Clin. Endocrinol. Metab.*, 41: 373–379 (1975).
- 37) Schulz, M., Scmoltdt, A., Donn, F. and Becker, H.: The pharmacokinetics of flutamide and its metabolites after a single oral dose and during chronic treatment. *Eur. J. Clin. Pharmacol.*, 34: 633–636 (1988).
- 38) Kobayashi, Y., Fukami, T., Shimizu, M., Nakajima, M. and Yokoi, T.: Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. *Drug Metab. Dispos.*, 40: 1080–1084 (2012).
- 39) Uetrecht, J.: N-oxydation of drugs associated with idiosyncratic drug reactions. *Drug Metab. Rev.*, 34: 651–665 (2002).
- 40) Aizawa, Y., Ikemoto, I., Kishimoto, K., Wada, T., Yamazaki, H., Ohishi, Y., Kiyota, H., Furuta, N., Sumuki, H. and Ueda, M.: Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. *Mol. Cell. Biochem.*, 252: 149–156 (2003).
- 41) Matsuzaki, Y., Nagai, D., Ichimura, E., Goda, R., Tomura, A., Doi, M. and Nishikawa, K.: Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. *J. Gastroenterol.*, 41: 231–239 (2006).
- 42) Ohbuchi, M., Miyata, M., Nagai, D., Shimada, M., Yoshinari, K. and Yamazoe, Y.: Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. *Drug Metab. Dispos.*, 37: 97–105 (2009).
- 43) Sicardi, S. M., Martirena, J. L. and Iglesias, M. T.: Mutagenic and analgesic activities of aniline derivatives. *J. Pharm. Sci.*, 80: 761–764 (1991).
- 44) Gago-Dominguez, M., Yuan, J. M., Castela, J. E., Ross, R. K. and Yu, M. C.: Regular use of analgesics is a risk factor for renal cell carcinoma. *Br. J. Cancer*, 81: 542–548 (1999).
- 45) Vaught, J. B., McGarney, P. B., Lee, M. S., Garner, C. D., Wang, C. Y., Linsmainer-Bednar, E. M. and King, C. M.: Activation of N-hydroxyphenacetin to mutagenic and nucleic acid-binding metabolites by acyltransfer, deacylation, and sulfate conjugation. *Cancer Res.*, 41: 3424–3429 (1981).
- 46) Wirth, P. J., Alewood, P., Calder, I. and Thorgeirsson, S. S.: Mutagenicity of N-hydroxy-2-acetylaminofluorene and N-hydroxy-phenacetin and their respective deacetylated metabolites in nitroreductase deficient *Salmonella* TA98FR and TA100FR. *Carcinogenesis*, 3: 167–170 (1982).
- 47) Jensen, C. B. and Jollow, D. J.: The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia. *Toxicol. Appl. Pharmacol.*, 111: 1–12 (1991).
- 48) Kobayashi, Y., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. *Biochem. Pharmacol.*, in press.
- 49) Yew, W. W. and Leung, C. C.: Antituberculosis drugs and hepatotoxicity. *Respirology*, 11: 699–707 (2006).
- 50) Shimizu, M., Fukami, T., Kobayashi, Y., Takamiya, M., Aoki, Y., Nakajima, M. and Yokoi, T.: A novel polymorphic allele of human arylacetamide deacetylase leads to diminished enzyme activity. *Drug Metab. Dispos.*, 40: 1183–1190 (2012).
- 51) Kobayashi, Y., Fukami, T., Nakajima, A., Watanabe, A., Nakajima, M. and Yokoi, T.: Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. *Drug Metab. Dispos.*, 40: 671–679 (2012).
- 52) Tenconi, L. T. and Beretta, E.: Urinary and biliary metabolites of rifampicin in different animal species. In: *The Problems of Species Differences and Statistics in Toxicology*, Proc. Europ. Soc. For study of drug Toxicity, Vol. II; Excerpta Med. Int. Congr. Ser. No. 198, Excerpta Medica, Amsterdam, pp. 80–85 (1970).
- 53) Chan, K.: A simultaneous determination of rifampin and 25-deacetyl-rifampicin in cerebrospinal fluid and plasma of rabbit by liquid chromatography. *Zhongguo. Yao. Li. Xue. Bao.*, 8: 555–559 (1987).
- 54) Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B. and Fowst, G.: Rifampicin, a general review. *Arzneimittelforschung*, 21: 1907–1977 (1971).
- 55) Gnat, A., Ginzberg, D., Lieman-Hurwitz, J., Zamir, R., Zakut, H. and Soreq, H.: Human acetylcholinesterase and butyrylcholinesterase are encoded by two distinct genes. *Cell. Mol. Neurobiol.*, 11: 91–104 (1991).
- 56) Karpel, R., Ben Aziz-Aloya, R., Sternfeld, M., Ehrlich, G., Ginzberg, D., Tarroni, P., Clementi, F., Zakut, H. and Soreq, H.: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. *Exp. Cell Res.*, 210: 268–277 (1994).
- 57) Chatonnet, A. and Lockridge, O.: Comparison of butyrylcholinesterase and acetylcholinesterase. *Biochem. J.*, 260: 625–634 (1989).
- 58) Takeda, M., Tanaka, T. and Okochi, M.: New drugs for Alzheimer's disease in Japan. *Psychiatry Clin. Neurosci.*, 65: 399–404 (2011).
- 59) Jbilo, O., Bartels, C. F., Chatonnet, A., Toutant, J. P. and Lockridge, O.: Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. *Toxicol.*, 32: 1445–1457 (1994).
- 60) Lockridge, O., Bartels, C. F., Vaughan, T. A., Wong, C. K., Norton, S. E. and Johnson, L. L.: Complete amino acid sequence of human serum cholinesterase. *J. Biol. Chem.*, 262: 549–557 (1987).
- 61) Pérez Guillermo, F., Martínez Pretel, C. M., Tarín Royo, F., Peña Macías, M. J., Alvarez Ossorio, J. A. and Vidal, C. J.: Prolonged suxamethonium-induced neuromuscular blockade asso-